Health ProductsAdvisory

Archived – Updated safety information regarding Crestor

· Published by Health Canada · Official notice

Details

Alert type: Advisory
Category: Drugs
Issue: Important Safety Information, Product Safety
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

Health Canada wishes to advise Canadians of safety concerns about Crestor®, a cholesterol lowering drug, when used at the highest recommended dosage of 40 mg daily. The risk of rhabdomyolysis (muscle breakdown) may be increased at higher doses. Health Canada recommends that all patients taking Crestor®, or any cholesterol lowering drug, should be using the lowest dose that will meet their treatment goal.

Health Canada is actively reviewing the safety profile associated with rosuvastatin (Crestor®), particularly the 40 mg dose, and is in receipt of additional safety information provided by its manufacturer, AstraZeneca Canada Inc.

In June 2004, Health Canada posted a Public Advisory about an association between Crestor and rhabdomyolysis, a rare but serious muscle disorder. The same month, AstraZeneca Canada Inc. issued a Dear Healthcare Professional Letter to advise Canadian healthcare professionals of this information.

Rhabdomyolysis is a condition that results in muscle breakdown and the release of muscle cell contents into the bloodstream. Symptoms of rhabdomyolysis include muscle pain, weakness, muscle tenderness, fever, dark urine, nausea, and vomiting. In severe cases, rhabdomyolysis can result in kidney failure and can be life threatening.

Since June 2004, Health Canada has received a further 6 reports of rhabdomyolysis in patients using Crestor®, which are under assessment.

All patients taking Crestor®, or any cholesterol lowering drug, are advised to report any unexplained muscle pain, muscle weakness or cramps, or any brown or discoloured urine, to their physician immediately.

Note: Health Canada issued another advisory on this topic on March 3, 2005. To access this advisory, visit: Health Canada advises patients about the risks of CRESTOR® (rosuvastatin).
 

Media enquiries

Jirina Vlk
Health Canada
613-957-2988

Public enquiries

613-957-2991
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime